Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.

Item
http://www.wikidata.org/entity/Q34554492
Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused ReviewRisk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.Left Atrial Appendage Thrombus Resolution with Reduced Dose Apixaban.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association.Switching, Adverse Effects and Use of Over-the-Counter Analgesics among Users of Oral Anticoagulants: A Pharmacy-based Survey.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation.Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.Direct Oral Anticoagulants for Very Elderly People With Atrial Fibrillation: Efficacy and Safe Enough?Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants.
P2860

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.

Item
http://www.wikidata.org/entity/Q34554492
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@ast
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@en
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@nl
type
label
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@ast
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@en
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@nl
prefLabel
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@ast
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@en
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Safety of switching from vitam ...... rom the Dresden NOAC registry.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932